Tim Smith

These data on patients in Japan with eczema suggest there was sustained effectiveness in these patients’ clinical signs and in patient-reported outcomes.

In this analysis, patterns of global access to biologic drugs for patients with atopic dermatitis were explored among 50 countries.

In recent findings presented at ACAAI 2024, patients, caregivers, and even emergency medical professionals were shown to face issues with regard to treatment of anaphylaxis reactions.

The Parental Self-efficacy in Managing Anaphylaxis (PSEMA) questionnaire was shown to be effective in assessing self-efficacy of parents in managing their childrens’ conditions.

A sample of some of the most significant developments in pulmonology from October is featured in this Month in Review summary.

The announcement by the FDA resulted from an agency review of data on oral phenylephrine and a determination of its ineffectiveness as an active ingredient.

In this geospatial analysis, findings indicate that geographic regions with more tanning bed facilities tend to report higher melanoma rates.

In this review of the month of October, some of the most notable advancements and news in the field of allergy were highlighted.

This interview with Kraft features a discussion regarding her team’s new data from the BATURA study on albuterol for patients’ asthma exacerbations.

Investigators highlighted the long-term cost-effectiveness of routine HCV screening as well as linkage-to-care for high-risk patients in emergency departments.

Despite the number of individuals with MASLD-related HCC without cirrhosis who report a low FIB-4, current care pathways may not identify such patients for additional assessments.

In this Month in Review summary, some of the most notable advancements and developments in the field of dermatology were highlighted.

The approval by the FDA of minocycline hydrochloride modified release capsules, also known as DFD-29, will allow for treatment of inflammatory lesions and erythema among adults.

In this analysis, investigators identified several markers such as monocyte-high-density lipoprotein cholesterol ratio and C-reactive protein values.

This interview from Fall Clinical highlights the broader implications of the phase 3 data resulting from the ARRECTOR trial on roflumilast foam for those with psoriasis.

This interview following Fall Clinical highlights new phase 3 data on patient-reported outcomes from the ARRECTOR study evaluating roflumilast foam for psoriasis.

This conference review highlights several of the most notable stories and recent data covered by HCPLive at the Fall Clinical Dermatology Conference.

This interview from Fall Clinical featured a discussion of new findings on upadacitinib (Rinvoq) for patients with atopic dermatitis.

These data suggest brodalumab’s safety profile is consistent with findings from long-term clinical trials, with no new occurrences of suicide and a low rate of fungal infection.

This interview at the Fall Clinical Dermatology Conference features a discussion with Stein Gold regarding the open-label extension of the phase 3 ADORING trial regarding tapinarof.

Stein Gold speaks in this interview about the new lebrikizumab (Ebglyss) data presented at the Fall Clinical Dermatology Conference.

Murina highlighted takeaways from her seminar-in-depth regarding the evolving therapeutic landscape of HS.

This discussion with Murina covers several tips for dermatologists to implement, 1 of which touched on omega-3 supplementation for ocular rosacea.

In her Fall Clinical interview, Murina highlighted several key takeaways related to her talk titled ‘Managing Psoriasis with Oral Therapy: 2024 & Beyond.’

This interview from Fall Clinical covers 2 additional tips for clinical practice as well as unmet needs among patients.

In this interview at Fall Clinical Dermatology, Ferris and Bhatia highlighted several elements of skin cancer detection and management as well as unmet needs of patients.

This Fall Clinical Dermatology Conference interview with Song features a discussion regarding several useful clinical pearls for dermatologists.

This interview features a discussion with Bhatia and Ferris regarding the necessity of collaboration between dermatologists and oncologists for skin cancer.

In this interview, Neal Bhatia, MD, and Laura Korb Ferris, MD, PhD, spoke on their Fall Clinical Conference talk titled ‘Beyond the Biopsy: Other Methods To Help Us Manage Skin Cancer.’

This interview with Bunick highlighted the LEVEL UP phase 3b/4 trial findings regarding upadacitinib treatment of patients with atopic dermatitis.